ECOG-ACRIN Office of Communications
Inquire by email
Philadelphia, November 29, 2017 — Antonio C. Wolff, MD, FACP, FASCO, a practicing medical oncologist and internationally regarded breast cancer researcher, has been named chair of the ECOG-ACRIN Cancer Research Group’s (ECOG-ACRIN) Breast Cancer Committee, effective immediately. Dr. Wolff is a professor of oncology at Johns Hopkins University and a member of the Johns Hopkins Kimmel Cancer Center in Baltimore, Md.
The ECOG-ACRIN Breast Cancer Committee designs and conducts clinical trials that span the entire disease continuum, from screening through treatment of advanced disease. Its members include investigators from both treatment and medical imaging disciplines, who together pursue scientific objectives related to drug interventions and imaging technologies. This committee has a distinguished history of practice-changing trials in breast cancer.
For the past four years, Dr. Wolff served as co-chair of the Breast Cancer Committee.
His expansive research experience coincides directly with the committee’s research aims. Among his research efforts: improving the treatment options of patients with breast cancer, improving accrual to clinical trials, the implementation of research findings in clinical practice, and improving quality of care.
He is also known for the development and implementation of prognostic and predictive biomarkers (tissue, blood, and imaging) in clinical practice, and research on ways to improve the survivorship experience of breast cancer patients. He has collaborated with radiology and laboratory investigators to develop new imaging technologies and blood-based tests as tools for predicting early response to drug treatments in patients with operable breast cancer and future risk of recurrence.
Dr. Wolff joined ECOG-ACRIN nearly 20 years ago while a young research fellow at Johns Hopkins, an institutional member of ECOG-ACRIN since 1970. He gained much of his early clinical trials expertise through the group’s practice of assigning junior investigators to co-lead clinical trials under the mentorship of experienced researchers.
He received his medical degree at the Universidade Federal do Rio de Janeiro in Brazil and trained in medical oncology at Johns Hopkins.
Dr. Wolff is an associate editor of the Journal of Clinical Oncology, past chair of the Clinical Practice Guidelines Committee of the American Society of Clinical Oncology, and is currently the executive officer for the Translational Breast Cancer Research Consortium.
He is a Komen Scholar and recipient of a Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute. In 2017, Clarivate Analytics (previously part of Thomson Reuters) recognized him as one of the world’s most highly cited researchers (top 1 percent in clinical medicine).
Dr. Wolff succeeds Kathy D. Miller, MD (Indiana University), who stepped down from the position earlier this month after her election as co-chair of the National Cancer Institute’s Breast Cancer Steering Committee.
The Breast Cancer Committee is part of ECOG-ACRIN’s Therapeutic Studies Program.
The ECOG-ACRIN Cancer Research Group is a membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer. ECOG-ACRIN comprises nearly 1100 member institutions in the United States and around the world. Approximately 12,000 physicians, translational scientists, and associated research professionals from the member institutions are involved in Group research, which is organized into three scientific programs: Cancer Control and Outcomes, Therapeutic Studies, and Biomarker Sciences. ECOG-ACRIN is supported primarily through National Cancer Institute research grant funding, but also receives funding from private sector organizations through philanthropy and collaborations. It is headquartered in Philadelphia, Pa. For more information, visit ecog-acrin.org or call 215.789.3631.